PDZK1IP1: A Potential Drug Target and Biomarker (G10158)

Target Name: PDZK1IP1

NCBI ID: G10158

PDZK1IP1

PDZK1IP1: A Potential Drug Target and Biomarker

PDZK1IP1, also known as PDZK1, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the PDZ family of proteins, which are known for their role in cell-cell adhesion and signaling. PDZK1IP1 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become a focus of research in the scientific community, with the potential to be a drug target or biomarker.

The PDZK1IP1 protein is composed of 215 amino acid residues and has a calculated molecular mass of 23.5 kDa. It is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract, and has been shown to localize to the endoplasmic reticulum (ER) and to be involved in the formation of tight junctions, which are a type of cell-cell adhesion.

PDZK1IP1 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of PDZK1IP1 are associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that arises from the ducts that carry bile from the pancreas to the small intestine. Additionally, PDZK1IP1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in disease, PDZK1IP1 has also been shown to be a potential drug target. Studies have shown that inhibiting the activity of PDZK1IP1 has the potential to treat several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, researchers have shown that inhibiting the activity of PDZK1IP1 can significantly reduce the growth of cancer cells, and that this effect is dose-dependent.

PDZK1IP1 has also been shown to be a potential biomarker for several diseases, including cancer. For example, researchers have shown that PDZK1IP1 levels are significantly elevated in the blood of patients with various types of cancer, and that these levels can be used as a biomarker for disease. Additionally, PDZK1IP1 has been shown to be expressed in the brains of patients with neurodegenerative diseases, and that this may be an indicator of the severity of the disease.

In conclusion, PDZK1IP1 is a protein that has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become a focus of research in the scientific community, with the potential to be a drug target or biomarker. Further studies are needed to fully understand the role of PDZK1IP1 in disease and to develop effective treatments.

Protein Name: PDZK1 Interacting Protein 1

Functions: May play an important role in tumor biology

The "PDZK1IP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDZK1IP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets